Iterum Therapeutics plc (Nasdaq: ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to ...

ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third ...

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens ...

U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- ...

Cefoxitin resistance in AmpC non-producers could be due to some other resistance mechanism such as, lack of permeation of porins (12). Inducible expression of chromosomal AmpC β -lactamases, although ...

Group I β-lactamases are major resistance determinants to β-lactam antibiotics. Despite intense study, the identity of the catalytic base, the direction of hydrolytic attack, and the functional ...

Riyadh, Saudi Arabia – KoçDigital joined government and industry leaders at the official launch of the Advanced Manufacturing and Production Center (AMPC), a flagship project supporting Saudi Arabia’s ...

KoçDigital joined government and industry leaders at the official launch of the Advanced Manufacturing and Production Center (AMPC), a flagship project supporting Saudi Arabia’s Vision 2030 ...

Addressing resistance. These interfering beliefs, sometimes unspoken, significantly impact an individual's ability to embrace change efforts. Leaders should not be discouraged by resistance. Instead, ...

Key support established at $0.194, with resistance at $0.198-$0.200. Volume spikes at 01:00 (470M) and 14:00 (386M) confirmed bullish breakouts. Notable hourly breakout at 19:28 pushed prices to ...